Name (Synonyms) | Correlation | |
---|---|---|
drug773 | Normal (9%) Saline Wiki | 1.00 |
drug981 | SAB-301 Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study aims to examine the tolerability of high dose of leflunomide in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.
Description: Number of subjects requiring leflunomide dose modifications
Measure: Tolerability of high dose leflunomide as measured by leflunomide dose modifications Time: 14 daysDescription: Number of subjects that discontinue leflunomide
Measure: Tolerability of high dose leflunomide as measured by discontinuation of leflunomide Time: 14 daysDescription: Number of Adverse Events observed in all subjects for the duration of the study
Measure: Tolerability of high dose leflunomide as measured by Adverse Events Time: 14 daysDescription: Number of patients admitted to hospital during study period
Measure: Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized Time: 14 daysDescription: The number of days to reach first fever normalization (criteria for normalization: temperature < 100.4 F)
Measure: Time to defervescence as measured in days while on treatment protocol Time: 14 daysDescription: Number of days to resolve other symptoms, as assessed by a standardized questionnaire for symptom assessment
Measure: Resolution of other COVID-19 symptoms measured in days while on treatment protocol Time: 14 days